Equillium Doses First Subject in EQ504 Phase 1 Clinical Trial
Equillium says the first subject has been dosed in its Phase 1 clinical trial of EQ504.
Story updates
12:32:44 PM UTC
SquawkNews
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-con
12:34:07 PM UTC
SquawkNews
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504Triggers Milestone Closing of $20 million in additional funding under previously announced equity private placement agreement; cash…